基于伏诺拉生方案根除幽门螺杆菌的研究进展

Research progress on the eradication of Helicobacter pylori based on the Vonoprazan regimen

伏诺拉生(VPZ)是新型抑酸药,其抑酸作用强大持久,优于传统质子泵抑制剂(PPI),可广泛应用于酸相关性疾病,目前在国内的适用证主要是反流性食管炎。越来越多研究发现对比基于PPI方案根除幽门螺杆菌(Hp),基于VPZ的方案能提高Hp根除成功率,而不良反应与之相当甚至更少,最新国内发布的Hp治疗指南也提到VPZ的应用,但并未明确用法。本文就目前VPZ用于Hp治疗的作用机制、使用方案、疗效以及安全性等方面进行了总结,旨在为探索VPZ用于治疗Hp感染的提供参考。

Vonoprazan(VPZ)is a new type of acid-suppressing drug,with a strong and long-lasting acid inhibitory effect,superior to traditional proton pump inhibitors(PPI),and can be widely used in acid-related diseases.Currently,its main indication in China is reflux esophagitis.More and more studies have found that compared to PPI-based regimens for eradicating Helicobacter pylori(Hp),the regimen based on VPZ can improve the success rate of Hp eradication,and the adverse reactions are equivalent or even fewer.The latest domestic guidelines for the treatment of Helicobacter pylori also mention the use of VPZ,but the usage is not clear.This article summarizes the mechanism of action,usage regimen,efficacy,and safety of VPZ in the treatment of Hp infection,aiming to provide a reference for exploring the use of VPZ in the treatment of Hp infection.